Ibio Inc
NASDAQ:IBIO
Ibio Inc
Other
Ibio Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ibio Inc
NASDAQ:IBIO
|
Other
$2.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
$45m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$440m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$10.9B
|
CAGR 3-Years
-372%
|
CAGR 5-Years
-161%
|
CAGR 10-Years
-34%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$366.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$542.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-5%
|
|
Ibio Inc
Glance View
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. The company is headquartered in New York City, New York and currently employs 105 full-time employees. The company went IPO on 2008-08-18. The firm is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The firm through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The firm operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.
See Also
What is Ibio Inc's Other?
Other
2.4m
USD
Based on the financial report for Dec 31, 2025, Ibio Inc's Other amounts to 2.4m USD.
